AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19151389 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral domain optical coherence tomography (SOCT)
Number of subjects: 90
Study 19151389 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (SLP)
Number of subjects: 90
Study 19151389 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 90
Study 19151389 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimetry (Octopus G1)
Number of subjects: 90
Study 19151389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution SOCT
Number of subjects: 90
Study 19153124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib-fulvestrant combination (fulvestrant 250 mg i.m. on day 1 plus tipifarnib 300 mg orally twice daily on days 1-21 every 28 days)
Number of subjects: 31
Study 19153124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib-fulvestrant combination
Number of subjects: 31
Study 19153124 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant alone (from prior studies)
Number of subjects: 31
Study 19153274 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction (MI) severity indicators
Number of subjects: 0
Study 19153274 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ST-segment elevation
Number of subjects: 0
Study 19153274 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent Q-waves
Number of subjects: 0
Study 19153274 — intervention group
Group type: EXPERIMENTAL
Intervention: Any major Q wave
Number of subjects: 0
Study 19153274 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum creatine kinase values
Number of subjects: 0
Study 19153274 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum creatine kinase-MB values
Number of subjects: 0
Study 19153274 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum troponin I values
Number of subjects: 0
Study 19153274 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent with shock
Number of subjects: 0
Study 19153274 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined severity score (PREDICT score)
Number of subjects: 0
Study 19153830 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy in women with intermediate CYP2D6 metabolizer status
Number of subjects: 297
Study 19153830 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen therapy in women with poor CYP2D6 metabolizer status
Number of subjects: 297
Study 19153830 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen therapy in women with extensive CYP2D6 metabolizer status
Number of subjects: 297
Study 19153830 — intervention group
Group type: COMPARATOR
Intervention: Comparison of poor metabolizers to intermediate plus extensive metabolizers
Number of subjects: 297
Study 19154581 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of a physician or medical professional in providing therapy
Number of subjects: 10189
Study 19154581 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircraft diversion due to IMEs
Number of subjects: 10189
Study 19154581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean number of IMEs per billion revenue passenger kilometers (rpk)
Number of subjects: 10189
Study 19154581 — intervention group
Group type: EXPERIMENTAL
Intervention: Common medical conditions reported
Number of subjects: 10189
Study 19154581 — intervention group
Group type: EXPERIMENTAL
Intervention: Common surgical conditions reported
Number of subjects: 10189
Study 19155249 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability measures (e.g., very-low frequency component <5.7 ln ms(2))
Number of subjects: 312
Study 19155249 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of sustained monomorphic VT during programmed electrical stimulation (PES)
Number of subjects: 312
Study 19155249 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall risk stratification methods
Number of subjects: 312
Study 19155319 — intervention group
Group type: EXPERIMENTAL
Intervention: Former SGA children (35 subjects)
Number of subjects: 803
Study 19155319 — intervention group
Group type: COMPARATOR
Intervention: Former AGA children (147 subjects)
Number of subjects: 803
Study 19155899 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Number of subjects: 100
Study 19155899 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 100
Study 19155899 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to IOM guidelines
Number of subjects: 100
Study 19155899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparous women
Number of subjects: 100
Study 19158200 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTSH-PET
Number of subjects: 63
Study 19158200 — intervention group
Group type: COMPARATOR
Intervention: basal PET
Number of subjects: 63
Study 19158205 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO genotype AA
Number of subjects: 640
Study 19158205 — intervention group
Group type: COMPARATOR
Intervention: FTO genotype
Number of subjects: 640
Study 19158212 — intervention group
Group type: EXPERIMENTAL
Intervention: Vending machine food selection (self-selected diet)
Number of subjects: 69
Study 19158975 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR (12.5-50 mg/day)
Number of subjects: 72
Study 19158975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 19158975 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 72
Study 19159848 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 38
Study 19159848 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stent with pioglitazone
Number of subjects: 38
Study 19161635 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 509
Study 19161635 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 509
Study 19161635 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 509
Study 19161635 — intervention group
Group type: COMPARATOR
Intervention: Mannitol and Methacholine
Number of subjects: 509
Study 19164198 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 19164344 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg x day(-1) prednisolone for 4 weeks
Number of subjects: 1888
Study 19165689 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FES-IM and gait robotics
Number of subjects: 6
Study 19165689 — intervention group
Group type: COMPARATOR
Intervention: FES-IM
Number of subjects: 6
Study 19165689 — intervention group
Group type: COMPARATOR
Intervention: Gait robot
Number of subjects: 6
Study 19165956 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of incidental intracranial aneurysms
Number of subjects: 0
Study 19165956 — intervention group
Group type: COMPARATOR
Intervention: Natural history of incidental intracranial aneurysms
Number of subjects: 0
Study 19166444 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir (IDet)
Number of subjects: 3637
Study 19167685 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (240 microg/kg/day) combined with G-CSF (10 microg/kg/day) for up to 9 days, starting plerixafor on day 4.
Number of subjects: 49
Study 19167685 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor and G-CSF combination treatment.
Number of subjects: 49
Study 19167838 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg intravenous) every 2 weeks of 28-day cycles until tumor progression; 30 Gy of hypofractionated stereotactic radiotherapy (HFSRT) in five fractions after the first cycle of bevacizumab.
Number of subjects: 25
Study 19167838 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with HFSRT
Number of subjects: 25
Study 19168793 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased T-bet(+) T-cell effectors
Number of subjects: 0
Study 19168793 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased expression of CXCR3 ligand MIG (CXCL9) and interleukin-15 (IL-15)
Number of subjects: 0
Study 19168793 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of MxA and STAT1 phosphorylation
Number of subjects: 0
Study 19168793 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased numbers of plasmacytoid dendritic cells
Number of subjects: 0
Study 19170709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing syndrome (CS) treatment
Number of subjects: 40
Study 19171730 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin extended release, dosage and duration not available
Number of subjects: 0
Study 19171730 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 19175499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin injected s.c. once daily at a prophylactic dose.
Number of subjects: 42
Study 19177575 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 pathway activation in patients with alcoholic liver disease
Number of subjects: 0
Study 19177575 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells from alcoholic liver disease patients
Number of subjects: 0
Study 19177575 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17-secreting cells in liver biopsies
Number of subjects: 0
Study 19177575 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IL-17(+) cells in liver with clinical scores
Number of subjects: 0
Study 19177575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic stellate cells in alcoholic liver disease
Number of subjects: 0
Study 19179301 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning followed by allogeneic transplantation with matched related (n=4) or umbilical cord (n=18) donor grafts
Number of subjects: 22
Study 19179301 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning followed by allogeneic transplantation
Number of subjects: 22
Study 19179301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation in CR1 (n=14)
Number of subjects: 22
Study 19179301 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning allografting
Number of subjects: 22
Study 19179314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with autologous CD34+ bone marrow cells transduced with a retroviral vector containing the ADA gene after nonmyeloablative conditioning with busulfan.
Number of subjects: 10
Study 19179484 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose BioLVR hydrogel (10 ml per site)
Number of subjects: 50
Study 19179484 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BioLVR hydrogel (20 ml per site)
Number of subjects: 50
Study 19179484 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose and High-dose BioLVR hydrogel
Number of subjects: 50
Study 19181369 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with paclitaxel and carboplatin, 4 cycles before interval debulking surgery (IDS) and 4 additional cycles after surgery.
Number of subjects: 56
Study 19181452 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment for 6 months
Number of subjects: 20
Study 19181452 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 20
Study 19181644 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1Ra)
Number of subjects: 47
Study 19181644 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1Ra) + low-dose dexamethasone (20 mg/wk)
Number of subjects: 47
Study 19181644 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1Ra
Number of subjects: 47
Study 19182205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg on days 1-21), Adriamycin (9 mg/m² intravenously on days 1-4), Dexamethasone (40 mg on days 1-4 and 17-20) with pegfilgrastim
Number of subjects: 69
Study 19182205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Adriamycin, and Dexamethasone (RAD)
Number of subjects: 69
Study 19187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30/70 (BIAsp 30)
Number of subjects: 52419
Study 19191590 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir-ritonavir (ATV/RTV) alone
Number of subjects: 34
Study 19191590 — intervention group
Group type: COMPARATOR
Intervention: NRTI discontinuation
Number of subjects: 34
Study 19191590 — intervention group
Group type: COMPARATOR
Intervention: Standard genotyping and single-genome sequencing (SGS)
Number of subjects: 34
Study 19191652 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc (CCR5 antagonist)
Number of subjects: 116
Study 19192300 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% nitrous oxide (n = 97)
Number of subjects: 204
Study 19192300 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen (n = 107)
Number of subjects: 204
Study 19192339 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 IU r-hFSH (n=48)
Number of subjects: 161
Study 19192339 — intervention group
Group type: EXPERIMENTAL
Intervention: 112.5 IU r-hFSH (n=45)
Number of subjects: 161
Study 19192339 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU r-hFSH (n=34)
Number of subjects: 161
Study 19192339 — intervention group
Group type: EXPERIMENTAL
Intervention: 187.5 IU r-hFSH (n=24)
Number of subjects: 161
Study 19192339 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 IU r-hFSH (n=10)
Number of subjects: 161
Study 19192339 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 161
Study 19192454 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 2876
Study 19192456 — intervention group
Group type: EXPERIMENTAL
Intervention: Days of alcohol use
Number of subjects: 115
Study 19192456 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in days of alcohol use
Number of subjects: 115
Study 19192962 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitors (mTORIs) such as sirolimus, temsirolimus, and everolimus
Number of subjects: 0
Study 19192962 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitors (mTORIs) in combination with chemotherapeutic agents
Number of subjects: 0
Study 19192962 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus for immunosuppression post-liver transplantation
Number of subjects: 0
Study 19192962 — intervention group
Group type: COMPARATOR
Intervention: mTOR inhibitors (mTORIs)
Number of subjects: 0
Study 19193344 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day for 8 weeks
Number of subjects: 30
Study 19193613 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting heart rate >76 beats per minute
Number of subjects: 129135
Study 19193613 — intervention group
Group type: COMPARATOR
Intervention: Resting heart rate <=62 beats per minute
Number of subjects: 129135
Study 19193613 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 50-64 at baseline
Number of subjects: 129135
Study 19193613 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with diabetes
Number of subjects: 129135
Study 19195603 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvolt T-wave alternans (MTWA) testing
Number of subjects: 566
Study 19195603 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological study (EPS)
Number of subjects: 566
Study 19195603 — intervention group
Group type: EXPERIMENTAL
Intervention: MTWA-directed strategy
Number of subjects: 566
Study 19195603 — intervention group
Group type: EXPERIMENTAL
Intervention: EPS-directed strategy
Number of subjects: 566
Study 19195603 — intervention group
Group type: COMPARATOR
Intervention: Both negative MTWA and EPS tests
Number of subjects: 566
Study 19196892 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher A1C
Number of subjects: 1620
Study 19196892 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 1620
Study 19196892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 1620
Study 19196892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum creatinine concentration
Number of subjects: 1620
Study 19196892 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Number of subjects: 1620
Study 19196892 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 1620
Study 19196892 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum alanine aminotransferase concentration
Number of subjects: 1620
Study 19196892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower age
Number of subjects: 1620
Study 19196892 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C and BMI combined
Number of subjects: 1620
Study 19199546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8800
Study 19204221 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin use
Number of subjects: 161808
Study 19204228 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-sitting panretinal photocoagulation (PRP)
Number of subjects: 155
Study 19204228 — intervention group
Group type: COMPARATOR
Intervention: 4-sitting panretinal photocoagulation (PRP)
Number of subjects: 155
Study 19204302 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR-measured lipoprotein particle concentration
Number of subjects: 27673
Study 19204302 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR-measured lipoprotein particle size
Number of subjects: 27673
Study 19204302 — intervention group
Group type: COMPARATOR
Intervention: Standard lipids
Number of subjects: 27673
Study 19204302 — intervention group
Group type: COMPARATOR
Intervention: Apolipoproteins
Number of subjects: 27673
Study 19204798 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH chemotherapy (etoposide, doxorubicin, vincristine, daily prednisone, bolus cyclophosphamide) followed by antiretroviral therapy (daily zidovudine, lamivudine, and alpha interferon-2a for up to one year)
Number of subjects: 19
Study 19204798 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH chemotherapy
Number of subjects: 19
Study 19207166 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-MNC
Number of subjects: 24
Study 19207166 — intervention group
Group type: COMPARATOR
Intervention: PB-MNC
Number of subjects: 24
Study 19208692 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in carbon monoxide (CO) concentration by 10 microg/m(3)
Number of subjects: 1050
Study 19208692 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in nitric oxide (NO) concentration by 10 microg/m(3)
Number of subjects: 1050
Study 19208692 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in nitrogen dioxide (NO2) concentration by 10 microg/m(3)
Number of subjects: 1050
Study 19208692 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in oxides of nitrogen concentration by 10 microg/m(3)
Number of subjects: 1050
Study 19208692 — intervention group
Group type: COMPARATOR
Intervention: Ozone (O3) and fine particulates
Number of subjects: 1050
Study 19210145 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (0.75 microg/kg, Q2W)
Number of subjects: 128
Study 19210158 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 19210163 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 2 doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 (10^7-TCID(50) administered intranasally)
Number of subjects: 50
Study 19210946 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex polypharmacy (use of 4 or more medications)
Number of subjects: 4035
Study 19210946 — intervention group
Group type: COMPARATOR
Intervention: Traditional mood stabilizers (lithium, divalproex, carbamazepine)
Number of subjects: 4035
Study 19210946 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex polypharmacy
Number of subjects: 4035
Study 19210946 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex regimens
Number of subjects: 4035
Study 19216617 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVATE rAHF-PFM (Baxter Healthcare Corporation)
Number of subjects: 234
Study 19216617 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 234
Study 19217019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg)
Number of subjects: 138
Study 19217176 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 to 80 mg
Number of subjects: 2117
Study 19217176 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2117
Study 19217176 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 2117
Study 19218820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin (IgIV) administered monthly for 12 months
Number of subjects: 10
Study 19220138 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use during sexual intercourse
Number of subjects: 6396
Study 19220138 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use
Number of subjects: 6396
Study 19220138 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 6396
Study 19220138 — intervention group
Group type: COMPARATOR
Intervention: Enrollment HIV status
Number of subjects: 6396
Study 19220909 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral self-regulation (BSR)
Number of subjects: 40
Study 19220909 — intervention group
Group type: COMPARATOR
Intervention: Adapted standard behavioral treatment (SBT)
Number of subjects: 40
Study 19220909 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BSR and SBT)
Number of subjects: 40
Study 19221274 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical regimen of 5-fluorouracil, 0.5%, cream
Number of subjects: 0
Study 19222627 — intervention group
Group type: EXPERIMENTAL
Intervention: qd IDet
Number of subjects: 1285
Study 19222627 — intervention group
Group type: COMPARATOR
Intervention: bid IGlarg
Number of subjects: 1285
Study 19223069 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (51.3 mmol per day) for 7 days
Number of subjects: 1881
Study 19223069 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (307.8 mmol per day) for 7 days
Number of subjects: 1881
Study 19224892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n = 109)
Number of subjects: 152
Study 19224892 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 43)
Number of subjects: 152
Study 19228281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic strategy comparing diagnostic test results with baseline imaging results
Number of subjects: 398